{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:03:18Z","timestamp":1793041398172,"version":"4.5.0"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T00:00:00Z","timestamp":1617753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research & Development, LLC","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National Health and Medical Research Council Practitioner Fellowship","award":["GNT1135920"],"award-info":[{"award-number":["GNT1135920"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,3,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>Given the benefits of sodium glucose co-transporter 2 inhibition (SGLT2i) in protecting against heart failure in diabetic patients, we sought to explore the potential impact of SGLT2i on the clinical features of patients presenting with myocardial infarction (MI) through a post hoc analysis of CANVAS Programme and CREDENCE trial.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>Individuals with type 2 diabetes and history or high risk of cardiovascular disease (CANVAS Programme) or type 2 diabetes and chronic kidney disease (CREDENCE) were included. The intervention was canagliflozin 100 or 300\u00a0mg (combined in the analysis) or placebo. MI events were adjudicated as ST-elevation myocardial infarction (STEMI), non-STEMI, and type 1 MI or type 2 MI. A total of 421 first MI events in the CANVAS Programme and 178 first MI events in the CREDENCE trial were recorded (83 fatal, 128 STEMI, 431 non-STEMI, and 40 unknown). No benefit of canagliflozin compared with placebo on time to first MI event was observed [hazard ratio (HR) 0.89; 95% confidence interval (CI) 0.75, 1.05]. Canagliflozin was associated with lower risk for non-STEMI (HR 0.78; 95% CI 0.65, 0.95) but suggested a possible increase in STEMI (HR 1.55; 95% CI 1.06, 2.27), with no difference in risk of type 1 or type 2 MI. There was no change in fatal MI (HR 1.22, 95% CI 0.78, 1.93).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Canagliflozin was not associated with a reduction in overall MI in the pooled CANVAS Programme and CREDENCE trial population. The possible differential effect on STEMI and Non-STEMI observed in the CANVAS cohort warrants further investigation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration<\/jats:title>\n                  <jats:p>ClinicalTrials.gov identifiers: NCT01032629, NCT01989754, and NCT02065791.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cvr\/cvab128","type":"journal-article","created":{"date-parts":[[2021,4,6]],"date-time":"2021-04-06T11:19:30Z","timestamp":1617707970000},"page":"1103-1114","source":"Crossref","is-referenced-by-count":20,"title":["Effects of canagliflozin on myocardial infarction: a <i>post hoc<\/i> analysis of the CANVAS programme and CREDENCE trial"],"prefix":"10.1093","volume":"118","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7401-7580","authenticated-orcid":false,"given":"Jie","family":"Yu","sequence":"first","affiliation":[{"name":"The George Institute for Global Health, UNSW Sydney, Level 5, 1 King Street, Newtown, 2042 Sydney, Australia"},{"name":"Department of Cardiology, Peking University Third Hospital, Level 5, 1 King Street, Newtown, 2042 Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingwei","family":"Li","sequence":"additional","affiliation":[{"name":"The George Institute for Global Health, UNSW Sydney, Level 5, 1 King Street, Newtown, 2042 Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2112-9535","authenticated-orcid":false,"given":"Phillip J","family":"Leaver","sequence":"additional","affiliation":[{"name":"Kolling Institute, Royal North Shore Hospital and University of Sydney, Pacific Highway St Leonards, 2065 Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9370-9913","authenticated-orcid":false,"given":"Clare","family":"Arnott","sequence":"additional","affiliation":[{"name":"The George Institute for Global Health, UNSW Sydney, Level 5, 1 King Street, Newtown, 2042 Sydney, Australia"},{"name":"Department of Cardiology, Royal Prince Alfred Hospital, 50 Missenden Road, Camperdown 2050 Sydney, Australia"},{"name":"Sydney Medical School, University of Sydney, Camperdown, 2050 Sydney, Australia"},{"name":"Faculty of Medicine, University of New South Wales, 18 High Street, Kensington 2052 Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7412-2519","authenticated-orcid":false,"given":"Mark D","family":"Huffman","sequence":"additional","affiliation":[{"name":"The George Institute for Global Health, UNSW Sydney, Level 5, 1 King Street, Newtown, 2042 Sydney, Australia"},{"name":"Department of Preventive Medicine and Centre for Global Cardiovascular Health, Northwestern University Feinberg School of Medicine, Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7402-9584","authenticated-orcid":false,"given":"Jacob A","family":"Udell","sequence":"additional","affiliation":[{"name":"Department of Medicine, Cardiovascular Division, Peter Munk Cardiac Centre, Toronto General Hospital and Women\u2019s College Hospital, University of Toronto, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlado","family":"Perkovic","sequence":"additional","affiliation":[{"name":"The George Institute for Global Health, UNSW Sydney, Level 5, 1 King Street, Newtown, 2042 Sydney, Australia"},{"name":"Faculty of Medicine, University of New South Wales, 18 High Street, Kensington 2052 Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth W","family":"Mahaffey","sequence":"additional","affiliation":[{"name":"Stanford Center for Clinical Research, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dick","family":"de Zeeuw","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8782-0420","authenticated-orcid":false,"given":"Greg","family":"Fulcher","sequence":"additional","affiliation":[{"name":"Sydney Medical School, University of Sydney, Camperdown, 2050 Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6504-0036","authenticated-orcid":false,"given":"David R","family":"Matthews","sequence":"additional","affiliation":[{"name":"Oxford Centre for Diabetes, Endocrinology and Metabolism and Harris Manchester College, University of Oxford, Mansfield Road, Oxford OX1 3TD, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne","family":"Shaw","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, LLC, 920 US-202, Raritan, NJ 08869, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1649-4979","authenticated-orcid":false,"given":"Norman","family":"Rosenthal","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, LLC, 920 US-202, Raritan, NJ 08869, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0490-7465","authenticated-orcid":false,"given":"Bruce","family":"Neal","sequence":"additional","affiliation":[{"name":"The George Institute for Global Health, UNSW Sydney, Level 5, 1 King Street, Newtown, 2042 Sydney, Australia"},{"name":"The Charles Perkins Centre, University of Sydney, John Hopkins Drive, 2006 Sydney, Australia"},{"name":"Faculty of Clinical Epidemiology, Imperial College London, Level 2, Faculty Building South Kensington Campus, SW7 2AZ London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma A","family":"Figtree","sequence":"additional","affiliation":[{"name":"The George Institute for Global Health, UNSW Sydney, Level 5, 1 King Street, Newtown, 2042 Sydney, Australia"},{"name":"Kolling Institute, Royal North Shore Hospital and University of Sydney, Pacific Highway St Leonards, 2065 Sydney, Australia"},{"name":"Sydney Medical School, University of Sydney, Camperdown, 2050 Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,4,7]]},"reference":[{"key":"2022031721053703100_cvab128-B1","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1161\/01.ATV.11.1.80","article-title":"High fasting plasma insulin is an indicator of coronary heart disease in non-insulin-dependent diabetic patients and nondiabetic subjects","volume":"11","author":"Ronnemaa","year":"1991","journal-title":"Arterioscler Thromb"},{"key":"2022031721053703100_cvab128-B2","first-page":"41","article-title":"Coronary heart disease mortality in relation with diabetes, blood glucose and plasma insulin levels. The Paris Prospective Study, ten years later","volume":"15","author":"Eschwege","year":"1985","journal-title":"Horm Metab Res Suppl"},{"key":"2022031721053703100_cvab128-B3","doi-asserted-by":"crossref","first-page":"154","DOI":"10.2337\/diacare.2.2.154","article-title":"Coronary heart disease incidence and cardiovascular mortality in Busselton with reference to glucose and insulin concentrations","volume":"2","author":"Welborn","year":"1979","journal-title":"Diabetes Care"},{"key":"2022031721053703100_cvab128-B4","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"key":"2022031721053703100_cvab128-B5","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1161\/01.CIR.0000087480.94275.97","article-title":"From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part I","volume":"108","author":"Naghavi","year":"2003","journal-title":"Circulation"},{"key":"2022031721053703100_cvab128-B6","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1161\/01.CIR.0000087481.55887.C9","article-title":"From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part II","volume":"108","author":"Naghavi","year":"2003","journal-title":"Circulation"},{"key":"2022031721053703100_cvab128-B7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2012.07.064","article-title":"Pathogenesis of acute coronary syndromes","volume":"61","author":"Crea","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2022031721053703100_cvab128-B8","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"2022031721053703100_cvab128-B9","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"2022031721053703100_cvab128-B10","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ahj.2013.05.007","article-title":"Rationale, design, and baseline characteristics of the canagliflozin cardiovascular assessment study (CANVAS)\u2014a randomized placebo-controlled trial","volume":"166","author":"Neal","year":"2013","journal-title":"Am Heart J"},{"key":"2022031721053703100_cvab128-B11","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/dom.12829","article-title":"Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): a randomized, placebo-controlled trial","volume":"19","author":"Neal","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"2022031721053703100_cvab128-B12","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1111\/dom.12924","article-title":"Optimizing the analysis strategy for the CANVAS Program\u2014a pre-specified plan for the integrated analyses of the CANVAS and CANVAS-R trials","volume":"19","author":"Neal","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"2022031721053703100_cvab128-B13","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1161\/CIR.0b013e31826e1058","article-title":"Third universal definition of myocardial infarction","volume":"126","author":"Thygesen","year":"2012","journal-title":"Circulation"},{"key":"2022031721053703100_cvab128-B14","doi-asserted-by":"crossref","first-page":"e618","DOI":"10.1161\/CIR.0000000000000617","article-title":"Fourth universal definition of myocardial infarction (2018)","volume":"138","author":"Thygesen","year":"2018","journal-title":"Circulation"},{"key":"2022031721053703100_cvab128-B15","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1136\/bmj.39057.406644.68","article-title":"What is heterogeneity and is it important?","volume":"334","author":"Fletcher","year":"2007","journal-title":"BMJ"},{"key":"2022031721053703100_cvab128-B16","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"2022031721053703100_cvab128-B17","doi-asserted-by":"crossref","first-page":"844","DOI":"10.14740\/jocmr2760w","article-title":"Increased hematocrit during sodium-glucose cotransporter 2 inhibitor therapy indicates recovery of tubulointerstitial function in diabetic kidneys","volume":"8","author":"Sano","year":"2016","journal-title":"J Clin Med Res"},{"key":"2022031721053703100_cvab128-B18","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3810\/pgm.2014.05.2753","article-title":"Safety and tolerability of canagliflozin in patients with type 2 diabetes mellitus: pooled analysis of phase 3 study results","volume":"126","author":"Usiskin","year":"2014","journal-title":"Postgrad Med"},{"key":"2022031721053703100_cvab128-B19","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/0002-8703(94)90679-3","article-title":"Hematocrit and the risk of cardiovascular disease--the Framingham study: a 34-year follow-up","volume":"127","author":"Gagnon","year":"1994","journal-title":"Am Heart J"},{"key":"2022031721053703100_cvab128-B20","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1161\/01.STR.16.5.765","article-title":"Hemorheology of the cerebral circulation in stroke","volume":"16","author":"Wood","year":"1985","journal-title":"Stroke"},{"key":"2022031721053703100_cvab128-B21","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1161\/CIRCULATIONAHA.107.187397","article-title":"Universal definition of myocardial infarction","volume":"116","author":"Thygesen","year":"2007","journal-title":"Circulation"},{"key":"2022031721053703100_cvab128-B22","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1161\/CIRCULATIONAHA.117.030012","article-title":"Sodium glucose cotransporter-2 inhibition in heart failure: potential mechanisms, clinical applications, and summary of clinical trials","volume":"136","author":"Lytvyn","year":"2017","journal-title":"Circulation"},{"key":"2022031721053703100_cvab128-B23","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2174\/1570161118666200317150359","article-title":"Diabetes mellitus, arterial stiffness and cardiovascular disease: clinical implications and the influence of SGLT2i","volume":"19","author":"Lamacchia","year":"2020","journal-title":"Curr Vasc Pharmacol"},{"key":"2022031721053703100_cvab128-B24","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1016\/j.amjcard.2019.10.028","article-title":"Potential mechanisms of sodium-glucose co-transporter 2 inhibitor-related cardiovascular benefits","volume":"124","author":"Verma","year":"2019","journal-title":"Am J Cardiol"},{"key":"2022031721053703100_cvab128-B25","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1038\/s41467-020-15983-6","article-title":"SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease","volume":"11","author":"Kim","year":"2020","journal-title":"Nat Commun"},{"key":"2022031721053703100_cvab128-B26","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1161\/CIRCULATIONAHA.118.038881","article-title":"Possible mechanism of hematocrit elevation by sodium glucose cotransporter 2 inhibitors and associated beneficial renal and cardiovascular effects","volume":"139","author":"Sano","year":"2019","journal-title":"Circulation"}],"container-title":["Cardiovascular Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cardiovascres\/advance-article-pdf\/doi\/10.1093\/cvr\/cvab128\/38377725\/cvab128.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cardiovascres\/article-pdf\/118\/4\/1103\/42950251\/cvab128.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cardiovascres\/article-pdf\/118\/4\/1103\/42950251\/cvab128.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T23:45:41Z","timestamp":1647560741000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cardiovascres\/article\/118\/4\/1103\/6214523"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,7]]},"references-count":26,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,4,7]]},"published-print":{"date-parts":[[2022,3,16]]}},"URL":"https:\/\/doi.org\/10.1093\/cvr\/cvab128","relation":{},"ISSN":["0008-6363","1755-3245"],"issn-type":[{"value":"0008-6363","type":"print"},{"value":"1755-3245","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,3,1]]},"published":{"date-parts":[[2021,4,7]]}}}